Olomorasib

Olomorasib (LY3537982) is an experimental anticancer drug which acts as an inhibitor of the G12C mutant form of Kirsten rat sarcoma virus (KRAS), an oncogene commonly present in several forms of cancer. It is in early stage clinical trials against lung and colorectal cancers and advanced solid tumors.^{[1][2][3][4][5]}

Olomorasib

Clinical data
Other names	LY3537982
Identifiers
IUPAC name 4-[(13aS)-10-chloro-8-fluoro-6-oxo-2-prop-2-enoyl-1,3,4,12,13,13a-hexahydropyrazino[2,1-d][1,5]benzoxazocin-9-yl]-2-amino-7-fluoro-1-benzothiophene-3-carbonitrile
CAS Number	2649788-46-3
PubChem CID	156472638
ChemSpider	115009373
UNII	C2VJ83PSN7
KEGG	D12853
Chemical and physical data
Formula	C25H19ClF2N4O3S
Molar mass	528.96 g·mol−1
3D model (JSmol)	Interactive image
SMILES C=CC(=O)N1CCN2[C@H](C1)CCOC3=C(C(=C(C=C3C2=O)F)C4=C5C(=C(SC5=C(C=C4)F)N)C#N)Cl
InChI InChI=1S/C25H19ClF2N4O3S/c1-2-18(33)31-6-7-32-12(11-31)5-8-35-22-14(25(32)34)9-17(28)20(21(22)26)13-3-4-16(27)23-19(13)15(10-29)24(30)36-23/h2-4,9,12H,1,5-8,11,30H2/t12-/m0/s1 Key:OZUPICRWMLEFCS-LBPRGKRZSA-N

See also

• ACBI3
• Adagrasib
• Divarasib
• MRTX1133
• RMC-9805
• Sotorasib